Cheryl Harth
Medical Oncology · Dallas, TXNPI 1407894413
Payments from drug & device makers
Across 113 payments — averaging $1991.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$118K
- Amgen$70K
- Janssen Research & Development, LLC$20K
- Novartis$7K
- Eisai Inc.$5K
- Seagen Inc.$2K
- plus $3K from 19 others
What the payments were for
- Consulting fees$12,22569%
- Travel & lodging$1,90211%
- Food & beverage$3,61120%
- Education$750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 6 | $118,158 |
| Amgen | 7 | $69,645 |
| Janssen Research & Development, LLC | 42 | $19,514 |
| Novartis | 8 | $7,401 |
| Eisai Inc. | 11 | $5,202 |
| Seagen Inc. | 2 | $2,155 |
| Merck | 4 | $459 |
| Bayer | 3 | $267 |
| Tesaro, Inc. | 2 | $238 |
| Johnson & Johnson | 2 | $229 |
| AbbVie | 3 | $227 |
| Pfizer | 3 | $142 |
| Astellas Pharma US Inc | 3 | $135 |
| AstraZeneca | 1 | $125 |
| Daiichi Sankyo Inc. | 1 | $122 |
| Puma Biotechnology, Inc. | 1 | $121 |
| Clovis Oncology, Inc. | 1 | $118 |
| Incyte Corporation | 1 | $116 |
| Gilead | 1 | $116 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $113 |
| Genentech, Inc. | 1 | $110 |
| Heron Therapeutics, Inc. | 1 | $110 |
| Jazz Pharmaceuticals Inc. | 1 | $87 |
| Siemens Medical Solutions USA, Inc. | 5 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $68 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$225,055 in reported general payments places this provider in the 60th percentile of 495 medical oncology providers in Texas.
Other medical oncology in Dallas
- Sawsan RashdanDallas$29.9M
- David GerberDallas$22.8M
- Joyce O'ShaughnessyDallas$20.8M
- Moshe LevyDallas$19.7M
- Minal BarveDallas$16.7M
- Andrew PaulsonDallas$11.5M
- Hans HammersDallas$11.4M
- James StraussDallas$9.1M
- Larry AndersonDallas$8.7M
- Heather McArthurDallas$7.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.